Holen Sie sich die Stockscreener-App
4.17
2.57%
-0.11
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience chief development officer sells shares worth $97,721 By Investing.com - Investing.com South Africa
Skye Bioscience chief development officer sells shares worth $97,721 - Investing.com India
Skye Bioscience CFO Kaitlyn Arsenault sells $216,652 in stock By Investing.com - Investing.com Australia
Skye Bioscience CEO Punit Dhillon sells $413,924 in stock By Investing.com - Investing.com Canada
Skye Bioscience CEO Punit Dhillon sells $413,924 in stock - Investing.com India
Skye Bioscience director Grayson Paul A. sells $432,061 in stock - Investing.com
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $18.67 - MarketBeat
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences - GlobeNewswire
Skye Bioscience to Present at Three Major Healthcare Investment Conferences in December | SKYE Stock News - StockTitan
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond - Yahoo Finance
Altium Capital Management LP Adjusts Stake in Skye Bioscience Inc - GuruFocus.com
Skye Bioscience hits halfway mark in obesity drug trial - Investing.com India
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor - Marketscreener.com
Skye Bioscience hits halfway mark in obesity drug trial By Investing.com - ழ தொலைக்காட்சி
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor - The Manila Times
Skye Bioscience's SWOT analysis: nimacimab's potential in obesity stock market - Investing.com Australia
Skye Bioscience (NASDAQ:SKYE) Trading Down 1.5%Should You Sell? - MarketBeat
(SKYE) Technical Pivots with Risk Controls - Stock Traders Daily
Skye Bioscience Reports Progress in Obesity Drug Trials - TipRanks
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
Skye Bioscience (SKYE) Scheduled to Post Earnings on Thursday - MarketBeat
Skye Bioscience Demonstrates Prominent Role of Peripheral - GlobeNewswire
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model - StockTitan
Skye Bioscience (SKYE) to Release Quarterly Earnings on Thursday - MarketBeat
Skye Bioscience to Announce Third Quarter 2024 Results - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Short Interest Update - MarketBeat
Skye Bioscience appoints new chairman to boost governance By Investing.com - Investing.com Canada
Long Term Trading Analysis for (SKYE) - Stock Traders Daily
Skye Bioscience appoints new chairman to boost governance - Investing.com India
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board - GlobeNewswire
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $18.67 - MarketBeat
Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes - TipRanks
Skye Bioscience (NASDAQ:SKYE) Shares Up 5.3%Still a Buy? - MarketBeat
Ex-Skye Bioscience VP's $4.9 Million Whistleblower Award Nixed - Bloomberg Law
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences - GlobeNewswire
Opera to Announce Third Quarter 2024 Financial Results on October 29, 2024 - Quantisnow
Coldwell Banker Real Estate Expands Global Presence to Tanzania and Zanzibar - Quantisnow
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - Benzinga
Scotiabank initates Skye Bioscience Inc (SKYE) stock to a Sector outperform - Knox Daily
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - MarketBeat
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Top 10 startups in Ophthalmology in San Diego, United States in Oct, 2024 - Tracxn
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore - MarketBeat
Point72 Asia Singapore Pte. Ltd. Invests $222,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):